What kind of kidney injury does Carmustine (BCNU) cause?

Chronic Interstitial Nephropathy — Slow, cumulative tubulointerstitial scarring — fibrosis, tubular atrophy and glomerulosclerosis with no discrete acute phase. The nitrosourea (carmustine/lomustine) lesion and delayed radioligand (radiation) nephropathy; often irreversible and detected only as a creeping creatinine months to years later. Other reported patterns: Thrombotic Microangiopathy.

How should kidney function be monitored during Carmustine (BCNU) therapy?

Serum creatinine / eGFR each course and at least annually for years after high cumulative exposure; Blood pressure and urinalysis (late proteinuria signals established scarring); CBC and LDH if conditioning-associated TMA is suspected.

How can kidney injury from Carmustine (BCNU) be prevented?

Limit cumulative dose and track lifetime exposure Maintain perfusion (avoid hypotension during high-dose infusion) Avoid additive nephrotoxins and minimize renal radiation dose

Who is at higher risk of kidney injury from Carmustine (BCNU)?

High cumulative dose (classically >=1200 mg/m2 / multiple courses); Prolonged treatment duration; Concurrent or prior other nitrosoureas; Total body irradiation / nephrotoxic co-medications (conditioning); Pre-existing renal impairment.

Back to explorer

Printable monograph

Nitrosourea alkylator

Carmustine (BCNU)

BiCNU · BCNU

Nitrosourea alkylator · approved 1977 · 7 citations · FAERS AKI reporting ROR 2.41 (95% CI 1.94–3.01, 80 AKI reports)

Dated evidence· through 2012

Fairly sourced6/9 · 5 signals

Met: 7 citations
Not met: 12+ references
Met: Accrued over 10+ years (span: 31y)
Met: Beyond single case reports
Not met: Peer-reviewed sources
Met: Landmark reference
Not met: Current through 2012
Met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A lipophilic nitrosourea whose cumulative dose silently scleroses the kidney over months to years.

ModerateNitrosourea alkylator

Malignant glioma and other brain tumorsMultiple myelomaHodgkin and non-Hodgkin lymphomaStem cell transplant conditioning (e.g., BEAM/BEAC)

§01

Signature kidney injury

Signature lesion

Chronic Interstitial Nephropathy

Insidious, cumulative-dose chronic nephrotoxicity; in classic high-cumulative-dose series the majority of long-term survivors develop reduced renal function, with small scarred kidneys. Acute injury is uncommon except via infusion hypotension or as part of conditioning-associated TMA/HUS.Source: Schacht et al., Cancer 1981

Onset & rechallenge

Time to injuryDelayed (>6 weeks / cumulative)

Chronic nephropathy months to years after cumulative exposure; conditioning-associated TMA appears within weeks.

Distilled from: “Delayed - months to years after cumulative exposure; conditioning-associated TMA appears within weeks.”

Long-term outlook & thresholds

Renal recoveryOften permanent

Cumulative-dose tubulointerstitial fibrosis is typically irreversible and can progress even after the nitrosourea is stopped; there is no specific antidote and it is managed as chronic kidney disease.PMID 7272960 (opens PubMed in a new tab)

CKD trajectory.: In classic high-cumulative-dose series the majority of long-term survivors develop reduced renal function, with small, scarred kidneys.

Cumulative-dose threshold

≥1200 mg/m² cumulative (classically, across multiple courses)

The majority of long-term survivors develop reduced renal function with small, scarred kidneys; the injury is delayed and can declare itself and worsen months to years after the last dose.PMID 7272960 (opens PubMed in a new tab)

Early-detection biomarkers

Urinary KIM-1 and NGAL — Proximal tubular injury. Proximal-tubule injury markers that rise before a detectable increase in serum creatinine after nephrotoxin exposure — relevant to carmustine's silently progressive tubulointerstitial lesion, where creatinine is a late and insensitive signal.PMID 21970770 (opens PubMed in a new tab)
Urinary β2-microglobulin (with cystatin C) — Tubulointerstitial dysfunction / low-molecular-weight proteinuria. NOT nitrosourea data: the cited study prospectively sampled 84 patients on aminoglycosides, vancomycin, amphotericin or calcineurin inhibitors — no nitrosourea and no anticancer agent — and in the 7 who developed AKI and had pre-AKI samples, median beta-2-microglobulin (alongside clusterin, cystatin C, KIM-1 and MCP-1) was significantly higher than in 14 matched non-AKI controls 1-3 days before AKI onset. It supplies the lead-time principle for low-molecular-weight tubular proteinuria — a mechanistic rationale for serial surveillance in carmustine's silently progressive tubulointerstitial lesion, not a carmustine-validated test.PMID 31296157 (opens PubMed in a new tab)

Long-term outcome and threshold data distilled from the agent's cited literature — educational, not a substitute for the primary sources.

Recovery across agents

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

Chronic Interstitial Nephropathy#1 · Signaturequalitative — no citable incidence
Slow, cumulative tubulointerstitial scarring — fibrosis, tubular atrophy and glomerulosclerosis with no discrete acute phase. The nitrosourea (carmustine/lomustine) lesion and delayed radioligand (radiation) nephropathy; often irreversible and detected only as a creeping creatinine months to years later.
Thrombotic MicroangiopathySecondaryqualitative — no citable incidence
Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.

§03

Kidney injury

Mechanism of kidney injury

Cumulative chloroethyl-nitrosourea exposure produces a slowly progressive tubulointerstitial lesion - tubular atrophy, interstitial fibrosis and glomerular sclerosis - typically without a discrete acute renal failure phase or major urinary abnormalities. In the transplant setting, BCNU contributes to endothelial injury that can precipitate radiation-augmented nephritis and chemotherapy-associated HUS/TMA. Infusion-related hypotension during high-dose carmustine can additionally cause prerenal/ischemic injury.

Clinical presentation

Gradual rise in BUN/creatinine and decline in GFR, often with minimal proteinuria or bland sediment; small, scarred kidneys on imaging in advanced cases. Conditioning-associated TMA presents with schistocytes, elevated LDH, thrombocytopenia and AKI.

Management

No specific antidote; discontinue further nitrosourea and manage as chronic kidney disease with blood-pressure control and avoidance of further insults. For conditioning-associated TMA, address triggers and provide supportive care. Established fibrosis is typically irreversible and can progress after the drug is stopped.Lesion-level management framework

Risk factors

High cumulative dose (classically >=1200 mg/m2 / multiple courses)
Prolonged treatment duration
Concurrent or prior other nitrosoureas
Total body irradiation / nephrotoxic co-medications (conditioning)
Pre-existing renal impairment

Prevention

Limit cumulative dose and track lifetime exposure
Maintain perfusion (avoid hypotension during high-dose infusion)
Avoid additive nephrotoxins and minimize renal radiation dose

Anticancer mechanism· how it treats cancer

Lipophilic chloroethyl-nitrosourea that crosses the blood-brain barrier and both alkylates (interstrand DNA cross-links at O6-guanine) and carbamoylates proteins. Used for malignant gliomas and other brain tumors, multiple myeloma, lymphomas, and as a transplant-conditioning agent (e.g., BEAM/BEAC).

§04

Clinical depth

Renal dose adjustment

No precise CrCl-banded schema; reduce or avoid in baseline renal impairment and cap cumulative lifetime dose. Hold subsequent courses for a sustained creatinine rise rather than waiting for symptomatic CKD.

Dialyzability & ESKD dosing

Highly lipophilic, rapidly metabolized parent drug; not meaningfully removed by dialysis and dialysis is not a management strategy. ESKD use is essentially limited to individualized conditioning protocols.

Differential diagnosis

Late nitrosourea nephropathy is a bland, slowly progressive tubulointerstitial/sclerotic lesion - contrast with acute infusion-hypotension ATN (temporally tied to dosing) and with conditioning HUS/TMA (microangiopathic hemolysis, thrombocytopenia). Cumulative-dose history is the key discriminator.

Monitoring

Serum creatinine / eGFR each course and at least annually for years after high cumulative exposure
Blood pressure and urinalysis (late proteinuria signals established scarring)
CBC and LDH if conditioning-associated TMA is suspected

Key trials & series

Schacht Cancer 1981 - landmark BCNU/methyl-CCNU brain-tumor cohort defining cumulative-dose interstitial fibrosis
Lonnerholm Bone Marrow Transplant 1991 - late renal dysfunction after BCNU-containing (BEAC) conditioning

Clinical pearls

Renal injury is dose-cumulative and DELAYED - it can declare itself, and worsen, months to years after the last dose.
Track lifetime nitrosourea exposure across BCNU/CCNU/methyl-CCNU; they share the same fibrotic lesion.
A bland sediment with creeping creatinine in a glioma/lymphoma survivor should prompt review of cumulative carmustine dose.

Where it strikes· nephron segments & injury signatures

Nephron segments

Interstitium

Supporting tissue around the tubules

Injury signatures

Chronic Interstitial Nephropathy Thrombotic Microangiopathy

Beyond the kidney — non-renal toxicities· 3 organ systems

Class-level context for the major non-renal toxicities of the Nitrosourea alkylator class.

Hematologic

Cytopenias, thrombosis, TMA

Myelosuppression; secondary malignancy risk

Neurologic

Neuropathy, encephalopathy, ICANS, PRES

Ifosfamide encephalopathy (chloroacetaldehyde)

Cardiac

Cardiomyopathy, QT, ischemia, myocarditis

High-dose cyclophosphamide cardiotoxicity

§05

References

6 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.

Evidence accrual

6 references · 1981–2001 · 1 since 1999

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

Case reports — ranked by strength· 1

Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.

CaseC · LimitedAcute kidney injury requiring dialysis following carmustine and etoposide during autologous stem cell transplantation.Li J et al. · Chemotherapy 2012 · PMID 23171711First reported case of carmustine-induced acute kidney injury with oliguria and proteinuria requiring hemodialysis during autologous stem cell transplantation conditioning.

FDA label — boxed warning & renal dosing· boxed warning

Quoted verbatim from this agent's current FDA label (Apr 2026) — not paraphrased or interpreted. Full label on DailyMed .

Boxed warning

WARNING: MYELOSUPPRESSION and PULMONARY TOXICITY Myelosuppression Carmustine for Injection, USP causes suppression of marrow function (including thrombocytopenia and leukopenia), which may contribute to bleeding and overwhelming infections, [see Warnings and Precautions (5.1) and Adverse Reactions (6) ] . Monitor blood counts weekly for at least 6 weeks after each dose. Adjust dosage based on nadir blood counts from the prior dose [see Dosage and Administration (2.1) ] . Do not administer a repeat course of Carmustine for Injection until blood counts recover. Pulmonary Toxicity Carmustine for Injection causes dose-related pulmonary toxicity. Patients receiving greater than 1400 mg /m 2 cumulative dose are at significantly higher risk than those receiving less. Delayed pulmonary toxicity can occur years after treatment, and can result in death, particularly in patients treated in childhood [see Adverse Reactions (6) and Use in Specific Populations (8.4) ] . WARNING: MYELOSUPPRESSION and PULMONARY TOXICITY See full prescribing information for complete boxed warning • Suppression of marrow function, notably thrombocytopenia and leukopenia, is the most common and severe of the toxic effects of Carmustine for Injection. Monitor blood counts. (5, 6). • Pulmonary toxicity from Carmustine for Injection appears to be dose related. Patients receiving greater than 1400 mg/m 2 cumulative…

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 4,612 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 5 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

Thrombotic Microangiopathycorroborated · ROR 6.49
Chronic Interstitial NephropathyNot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.

Thrombotic Microangiopathy

ROR 6.4995% CI 4.27–9.88· 22 reports

Acute Interstitial Nephritis

ROR 4.6395% CI 2.95–7.27· 19 reports

Acute Tubular Necrosis

ROR 2.7895% CI 1.25–6.19· 6 reports

Glomerular Injury / Proteinuria

ROR 1.8895% CI 1.06–3.31· 12 reports

Hemorrhagic Cystitis

ROR 1.7895% CI 1.22–2.59· 27 reports

FAERS outcomes & reporting trend· 25.8% of reports w/ death · 30.7% w/ hospitalization

25.8%

Reported with a death outcome

1,192 of 4,612 reports

30.7%

Reported with hospitalization

1,417 of 4,612 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 5 systems · 4,612 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 2.4195% CI 1.94–3.01· 80 AKI reports ·AKI is reported disproportionately more often than for other drugs (CI entirely above 1) — a hypothesis-generating signal, not proof of causation.

Blood & lymphatic

Febrile Neutropenia391Thrombocytopenia250Neutropenia206Anaemia116Pancytopenia105

Immune / infection

Pneumonia202Infection177Sepsis159Septic Shock101

Gastrointestinal

Mucosal Inflammation219Diarrhoea159Nausea91Vomiting83

General / constitutional

Pyrexia239Brain Oedema137

Respiratory

Respiratory Failure86Pulmonary Embolism81

Guidelines & consensus· 14

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

ADQIConventional cytotoxic chemotherapy-associated nephrotoxicity: consensus report of the 34th Acute Disease Quality Initiative (ADQI) WorkgroupKidney Int 2026 · PMID 41881107Cisplatin is identified as a leading cytotoxic nephrotoxin; the workgroup details preventive measures (adequate isotonic hydration, correction of volume depletion, avoidance of concurrent nephrotoxins, attention to electrolyte/magnesium wasting) and management of cisplatin-associated AKI, with a research agenda for knowledge gaps.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Carmustine (BCNU) sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Lomustine (CCNU)

Gleostine · Nitrosourea alkylator

Profile

Cumulative interstitial nephritis and CKD.

CIN

Moderate#1 · 76% phenotype match

Lutetium-177 Dotatate

Lutathera · Radioligand therapy (PRRT)

Profile

Peptide receptor radionuclide therapy; proximal tubular radiation nephropathy is dose-limiting — amino-acid co-infusion is renoprotective.

CINTMA

Moderate#2 · 69% phenotype match

Busulfan

Myleran · Alkylator

Profile

Conditioning-regimen TMA risk.

TMA

Moderate#3 · 53% phenotype match

Fotemustine

Muphoran · Nitrosourea (alkylating)

Profile

Class delayed cumulative tubulointerstitial/ATN; usually mild; acute signal often really cisplatin.

CINATNLYTE

Moderate#4 · 53% phenotype match

Nimustine (ACNU)

Nidran · Nitrosourea (alkylating)

Profile

Water-soluble nitrosourea; renal risk inferred at class level; cumulative delayed tubulointerstitial injury; DLT is myelosuppression.

CINATNLYTE

Moderate#5 · 52% phenotype match

Lutetium-177 PSMA-617 (vipivotide)

Pluvicto · Radioligand therapy (PSMA)

Profile

PSMA-targeted radioligand for prostate cancer; renal radiation exposure and xerostomia.

CINLYTE

Moderate#6 · 43% phenotype match

Compare Carmustine (BCNU) with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Alkylating agents

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.

Who studies this

The leading contributors to Carmustine (BCNU)’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Carmustine (BCNU); the PMIDs beside each name are up to three of their most recent papers on it, not the full count.

Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 11 clinical records among all 27 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.